-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
OncoSec Medical (NASDAQ:ONCS) Coverage Initiated at StockNews.com
OncoSec Medical (NASDAQ:ONCS) Coverage Initiated at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued to investors on Thursday. The firm set a "sell" rating on the biotechnology company's stock.
Separately, BTIG Research cut OncoSec Medical from a "buy" rating to a "neutral" rating in a research report on Monday, November 14th.
Get OncoSec Medical alerts:OncoSec Medical Trading Down 8.0 %
ONCS opened at $1.61 on Thursday. The stock has a market cap of $4.78 million, a PE ratio of -0.08 and a beta of 1.48. The stock's 50 day simple moving average is $8.03 and its 200-day simple moving average is $13.07. OncoSec Medical has a 1 year low of $1.55 and a 1 year high of $31.90.
Institutional Trading of OncoSec Medical
An institutional investor recently raised its position in OncoSec Medical stock. Renaissance Technologies LLC grew its position in shares of OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 48.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,898 shares of the biotechnology company's stock after buying an additional 23,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.19% of OncoSec Medical worth $54,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 13.22% of the company's stock.About OncoSec Medical
(Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
See Also
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued to investors on Thursday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新聞網的投資分析師在週四發佈給投資者的一份研究報告中假設了OncoSec Medical(納斯達克代碼：ONCS-GET Rating)的股票。該公司對這家生物技術公司的股票設定了“賣出”評級。
Separately, BTIG Research cut OncoSec Medical from a "buy" rating to a "neutral" rating in a research report on Monday, November 14th.
另外，BTIG Research在11月14日星期一的一份研究報告中將OncoSec Medical的評級從“買入”下調至“中性”。
OncoSec Medical Trading Down 8.0 %
OncoSec醫療降價8.0%
ONCS opened at $1.61 on Thursday. The stock has a market cap of $4.78 million, a PE ratio of -0.08 and a beta of 1.48. The stock's 50 day simple moving average is $8.03 and its 200-day simple moving average is $13.07. OncoSec Medical has a 1 year low of $1.55 and a 1 year high of $31.90.
ONCS週四開盤報1.61美元。該股市值為478萬美元，本益比為-0.08，貝塔係數為1.48。該股的50日簡單移動均線切入位為8.03美元，200日簡單移動均線切入位為13.07美元。OncoSec Medical的一年低點為1.55美元，一年高位為31.90美元。
Institutional Trading of OncoSec Medical
OncoSec醫療的制度性交易
About OncoSec Medical
關於OncoSec醫療
(Get Rating)
(獲取評級)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
OncoSec醫療公司是一家晚期免疫腫瘤學公司，專注於設計、開發和商業化基於DNA的腫瘤內療法，以刺激和增強用於癌症治療的抗腫瘤免疫反應。該公司的產品線包括用於治療晚期黑色素瘤的Keynote-695處於第二階段試驗；用於治療新冠肺炎的Tavo+SARS-CoV-2刺突糖蛋白處於第一階段臨床試驗；以及用於治療頭頸部鱗狀細胞癌的Tavo+epacadostat+pembrolizumab正處於第一階段臨床試驗。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- 免費獲取StockNews.com關於OncoSec Medical(ONCS)的研究報告
- 企業產品合作夥伴是否得到公平評價？
- WhatsApp合作夥伴關係是否會提振MercadoLibre的收益？
- 2023年中型股可能翻一番
- 馬倫汽車簽署新合作夥伴後股價上漲
- REV集團引領專用車製造商走高
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受OncoSec醫學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對OncoSec Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧